From: The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review
Country/countries | Name of subgroup | First author & publication year | Sample size | Mean age | Loss of ambulation (%) | Time point for follow up | Loss of Ambulation (n)@FU | Loss of ambulation (%)@FU |
---|---|---|---|---|---|---|---|---|
Italy | Ambulatory <350Â m(6MWT), <7y | Pane, 2014 [34] | 9 | 5.8 | 0 | 3y | 2 | 22.22 |
Ambulatory ≥350 m(6MWT), <7y | 19 | 6.16 | 1 | 5.26 | ||||
Ambulatory <350 m(6MWT), ≥7y | 25 | 9.87 | 16 | 64.00 | ||||
Ambulatory ≥350 m(6MWT), ≥7y | 43 | 8.9 | 5 | 11.63 | ||||
Ambulatory-boys | 96 | NR | 1y | 3 | 3.00 | |||
2y | 16 | 17.00 | ||||||
3y | 27 | 29.00 | ||||||
Italy; Belgium | Ambulatory ≥100 m | Pane, 2014 [42] | 191 | 7.9 | 1y | 4 | 2.10 | |
NR | Boys | Mah, 2012 [44] | 340 | 12.0 | 43 | 194 | 57.06 | |
Sweden | All DMD | Soderpalm, 2012 [45] | 24 | NR | 17 | 4y | 9 | 38.00 |
UK | Boys | Ricotti, 2012 [47] | 400 | NR | 7Y | NR | Median loss of ambulation was 14Â years in Daily versus 12Â years in Intermittent prednisolone |